Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Aurora Cannabis Inc.NASDAQ: ACB
Depreciation & Amortization · Q4 FY2026 · quarter ended Mar 2026
Depreciation & amortization turns negative
Q4 FY2026 depreciation & amortization was -CA$4.62M, compared with CA$5.95M a year earlier. Trailing-twelve-month depreciation & amortization was CA$13.44M. Over 3 fiscal years it compounded at -35.3% a year.
Context
- Depreciation & amortization amounted to 4.4% of revenue in FY2026, down 2.1 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -CA$4.62M or moves back toward the trailing-twelve-month quarterly average of CA$3.36M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the income statement
- Latest · FY2026
- 14.23M CAD
- Year-over-year change
- -36.9%
- 4-year CAGR
- -37.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 14.23M | -36.9% |
| FY2025 | 2025-03-31 | 22.55M | -31.8% |
| FY2024 | 2024-03-31 | 33.07M | -37.1% |
| FY2023 | 2023-03-31 | 52.59M | -43.9% |
| FY2022 | 2022-06-30 | 93.66M | — |
Depreciation & Amortization vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -40.4% is the lowest of 10, against a peer median of -2.9%.
- Depreciation & amortization amounts to 4.3% of revenue for ACB, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$39.79M CAD | -7.7% | -14.0% | 12.7% | |
| LTM Apr 2026 | CA$20.62M CAD | -9.4% | -6.9% | 3.1% | |
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | CA$13.44M CAD | -40.4% | -35.3% | 4.3% | |
| LTM Mar 2026 | $9.77M USD | — | -23.7% | 7.2% | |
| LTM Mar 2026 | $9.76M USD | -2.9% | +88.7% | 4.4% | |
| LTM Mar 2026 | $6.34M USD | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $3.84M USD | -39.2% | -5.9% | 9.9% | |
| LTM Mar 2026 | $1.85M USD | -6.7% | +9.9% | 0.5% | |
| LTM Mar 2026 | $528K USD | +7.3% | -17.1% | 6.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| Peer median (excluding ACB) | — | -2.9% | -5.9% | 6.8% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 221.34M | 223.8M | 270.28M | 343.29M | 321.42M |
| Cost of Revenue | 200.11M | 209.02M | 138.82M | 155.69M | 304.67M |
| Gross Profit | 21.23M | 14.78M | 131.46M | 187.61M | 16.75M |
| Gross Margin | 9.6% | 6.6% | 48.6% | 54.6% | 5.2% |
| Research & Development | 10.39M | 5.77M | 3.57M | 3.68M | 6.01M |
| Selling, General & Admin | 188.99M | 170.48M | 156.88M | 166.47M | 173.95M |
| Operating Expenses | 252.67M | 221.98M | 177.91M | 182.66M | 179.96M |
| Depreciation & Amortization | 93.66M | 52.59M | 33.07M | 22.55M | 14.23M |
| EBITDA | (1.55B) | (135M) | (12.34M) | 51.35M | (148.99M) |
| EBITDA Margin | -702.4% | -60.3% | -4.6% | 15.0% | -46.4% |
| Operating Income | (231.45M) | (207.19M) | (46.45M) | 4.95M | (163.21M) |
| Operating Margin | -104.6% | -92.6% | -17.2% | 1.4% | -50.8% |
| Interest Income | 4.51M | 19M | 12.81M | 11.51M | 5.86M |
| Interest Expense | 71.81M | 39.46M | 14.19M | 8.42M | 1.81M |
| Other Income / Expenses | (1.49B) | (576.51M) | (13.15M) | 15.43M | 106.54M |
| Income Before Tax | (1.72B) | (783.7M) | (59.6M) | 20.38M | (56.67M) |
| Pre-Tax Margin | -777.1% | -350.2% | -22.1% | 5.9% | -17.6% |
| Income Tax Expense | (2.14M) | 16.55M | (554K) | 4.62M | 2.1M |
| Net Income | (1.72B) | (816.63M) | (69.33M) | 1.59M | (122.07M) |
| Net Margin | -776.0% | -364.9% | -25.6% | 0.5% | -38.0% |
| EPS (Basic) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| EPS (Diluted) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| Weighted Avg Shares | 21.49M | 32.27M | 51.26M | 54.88M | 56.71M |
| Weighted Avg Shares (Diluted) | 21.49M | 32.27M | 51.26M | 55.75M | 56.71M |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.